Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) to Present at the 27th Annual ROTH Conference
SAN DIEGO
- March 4, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD),
the pioneer in developing targeted therapeutic devices to address infectious
diseases and cancer, today announced that James A. Joyce, Aethlon Medical CEO,
is scheduled to present a corporate overview at the 27th Annual ROTH Conference
on March 10, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California. To
learn more about the ROTH Conference click
here.
A live
webcast of the presentation will be available on the investor relations page of
the Company's corporate website at http://wsw.com/webcast/roth29/aemd.
A replay of the presentation will be available for 365 days.
Details of the presentation are
as follows:
Event:
27th Annual ROTH Conference
Date: Tuesday, March 10, 2015
Time: 5:30 pm PT
Place: The Ritz-Carlton Hotel (Laguna Niguel, CA)
Date: Tuesday, March 10, 2015
Time: 5:30 pm PT
Place: The Ritz-Carlton Hotel (Laguna Niguel, CA)
Read this release in full at http://www.investorideas.com/CO/AEMD/news/2015/03041.asp
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease, cancer and neurodegenerative disorders. The company's lead
product is the Aethlon Hemopurifier®, a first-in-class device that selectively
targets the rapid elimination of circulating viruses and tumor-secreted
exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority
owned subsidiary that is advancing exosome-based products to diagnose and
monitor cancer, infectious disease and neurological disorders. Additional
information can be found online at http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when needed,
the Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies, news
submissions, content marketing and online advertising. Contact each company
directly for press release questions. Disclosure is posted on each release if
required but otherwise the news was not compensated for and is published for
the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
Pharma stock update by epicresearch.co ,BAL PHARMA LTD is looking strong on charts, if it sustains above 80 levels. We advise buying around 80 levels with strict stop loss of 74 for the targets of 86-92 levels.
ReplyDelete